At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
DRTS Alpha Tau Medical
Market Closed 06-12 16:00:00 EDT
9.85
+0.17
+1.76%
盘后9.60
-0.25-2.54%
18:51 EDT
High10.20Low9.70Vol857.47K
Open9.77D1 Closing9.68Amplitude5.17%
Mkt Cap866.90MTradable Cap564.93MTotal Shares88.01M
T/O8.55MT/O Rate1.50%Tradable Shares57.35M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Wall Street Analysts Are Bullish on Top Healthcare Picks
TIPRANKS  ·  01:00
Wall Street Analysts Are Bullish on Top Healthcare Picks
Alpha Tau Medical Says FDA Clears Additional Patients, Sites for Alpha DaRT Trial in Glioblastoma
MT Newswires Live  ·  06-11 21:02
Alpha Tau Medical Says FDA Clears Additional Patients, Sites for Alpha DaRT Trial in Glioblastoma
Alpha Tau Receives FDA Clearance to Complete Enrollment in Regain Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control
THOMSON REUTERS  ·  06-11 20:30
Alpha Tau Receives FDA Clearance to Complete Enrollment in Regain Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control
Alpha Tau Medical - to Resume Recruitment for Remaining Seven Patients in Regain Trial
THOMSON REUTERS  ·  06-11 20:30
Alpha Tau Medical - to Resume Recruitment for Remaining Seven Patients in Regain Trial
Alpha Tau Medical - FDA Authorizes Two Additional U.S. Cancer Centers to Join Regain Trial
THOMSON REUTERS  ·  06-11 20:30
Alpha Tau Medical - FDA Authorizes Two Additional U.S. Cancer Centers to Join Regain Trial
Top Executive Makes Major Move With Alpha Tau Medical Stock
TIPRANKS  ·  06-05
Top Executive Makes Major Move With Alpha Tau Medical Stock
Alpha Tau Medical CFO Raphi Levy disposes of $352,606 in common shares
Reuters  ·  06-05
Alpha Tau Medical CFO Raphi Levy disposes of $352,606 in common shares
Alpha Tau Medical Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Dow Jones  ·  06-04
Alpha Tau Medical Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Alpha Tau Medical Is Maintained at Overweight by Barclays
Dow Jones  ·  06-04
Alpha Tau Medical Is Maintained at Overweight by Barclays
Alpha Tau Medical Ltd (DRTS) Receives a Buy from Barclays
TIPRANKS  ·  06-04
Alpha Tau Medical Ltd (DRTS) Receives a Buy from Barclays
Alpha Tau, Tolmar announce strategic collaboration agreement
TIPRANKS  ·  06-03
Alpha Tau, Tolmar announce strategic collaboration agreement
Alpha Tau Medical, Tolmar International Agree to Develop, Commercialize Prostate Cancer Therapy
MT Newswires Live  ·  06-03
Alpha Tau Medical, Tolmar International Agree to Develop, Commercialize Prostate Cancer Therapy
Alpha Tau, Tolmar partner to develop, commercialize Alpha DaRT for U.S. prostate cancer patients
Reuters  ·  06-03
Alpha Tau, Tolmar partner to develop, commercialize Alpha DaRT for U.S. prostate cancer patients
Alpha Tau Medical - Tolmar Granted Exclusive U.S. Rights for Prostate Cancer, Option for Bladder Cancer
THOMSON REUTERS  ·  06-03
Alpha Tau Medical - Tolmar Granted Exclusive U.S. Rights for Prostate Cancer, Option for Bladder Cancer
Alpha Tau Medical - Tolmar to Invest $15M in Manufacturing, $20M Equity at $11.99/Share, up to $161.5M in Milestones
THOMSON REUTERS  ·  06-03
Alpha Tau Medical - Tolmar to Invest $15M in Manufacturing, $20M Equity at $11.99/Share, up to $161.5M in Milestones
Alpha Tau Medical - to Manufacture Alpha Dart for Tolmar at 60% of Net Sales Price
THOMSON REUTERS  ·  06-03
Alpha Tau Medical - to Manufacture Alpha Dart for Tolmar at 60% of Net Sales Price
Alpha Tau Medical - up to $96.5M in Development and $65M in Commercial Milestone Payments Agreed
THOMSON REUTERS  ·  06-03
Alpha Tau Medical - up to $96.5M in Development and $65M in Commercial Milestone Payments Agreed
Alpha Tau Medical Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Dow Jones  ·  06-03
Alpha Tau Medical Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Alpha Tau Medical Reports Data Showing Alpha DaRT Increases Overall Survival for Patients With Pancreatic Cancer
MT Newswires Live  ·  06-01
Alpha Tau Medical Reports Data Showing Alpha DaRT Increases Overall Survival for Patients With Pancreatic Cancer
Alpha Tau reports 11.2-month median survival in pooled Phase I/II Alpha DaRT pancreatic cancer studies at ASCO 2026
Reuters  ·  06-01
Alpha Tau reports 11.2-month median survival in pooled Phase I/II Alpha DaRT pancreatic cancer studies at ASCO 2026

Introduction

Company Name.
Alpha Tau Medical
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Issue price:
--